Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by de Braud
Tebentafusp induces systemic immune activation, but tumor immune remodeling remains incompletely validated: a narrative review in metastatic uveal melanoma
Abstract Background: Tebentafusp improves survival in HLA-A*02:01-positive metastatic uveal melanoma, yet the human evidence linking early systemic immune activation to remodeling of metastatic tumors is dispersed across overlapping translational reports. Methods: We performed a PRISMA-style, search-informed narrative review and descriptive evidence mapping of human reports evaluating baseline or on-treatment immune measurements in tebentafusp-treated uveal melanoma.
Reliability of core needle biopsy for HER2-low early-stage breast cancer - Clinical and Translational Oncology
Abstract The reliability of core needle biopsy (CNB) for HER2-positive breast cancer is well established. However, data on HER2-low and the potential for inconsistencies with surgical samples are limited. Concordance between CNB and surgical samples was assessed using the unweighted Cohen kappa statistic (Kc) in a consecutive series of 776 treatment-naïve early-stage breast cancer patients.
Cyclic Fasting-Mimicking Diet Plus Bortezomib and Rituximab Is an Effective Treatment for Chronic Lymphocytic Leukemia
Cyclic fasting and fasting-mimicking diets (FMD) have been consistently found to promote additive or synergistic antitumor effects when combined with standard anticancer treatments in murine models of human malignancies, including melanoma, breast, colorectal, and lung cancer (1–6).
Development of a single-visit protocol for the management of pregnancy of unknown location following in vitro fertilization: a retrospective study
Pregnancy of unknown location (PUL) is the term used when it is not possible to visualize a pregnancy on transvaginal ultrasound scan (TVUS) in a clinically stable woman with a positive pregnancy test (Banerjee et al., 1999). This concept was developed in recognition of the high diagnostic accuracy of TVUS, which enables a skilled operator to detect any pregnancy large enough to potentially cause significant complications.
Cyclic fasting-mimicking diet plus bortezomib and rituximab is an effective treatment for chronic lymphocytic leukemia
This content is only available via PDF. This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license. This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License .
Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial
Sharma, P. et al. (2016) Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. Lancet Oncology, 17(11), pp. 1590-1598. (doi: 10.1016/S1470-2045(16)30496-X) (PMID:27733243) (PMCID:PMC5648054) Full text not currently available from Enlighten. Abstract Summary. Background: Few effective treatments exist for patients with advanced urothelial carcinoma that has progressed after platinum-based chemotherapy.
Comparative Genomic Analysis and Clinical Outcomes of BRAF-mutated Advanced Biliary Tract Cancers
Purpose: BRAF mutations are rare in Biliary Tract Cancers (BTC), but of interest given the recent developments in targeted therapy for BTC. We investigated the clinical outcomes in a cohort of BRAF-mutant advanced BTC treated with first-line chemotherapy. Furthermore, we investigated the genomic landscape of BRAF Class I, II and III mutations in the intrahepatic cholangiocarcinoma (iCCA) subgroup of BTC. Experimental Design: We analyzed two, non-overlapping cohorts.
Assessing the safety and activity of cabozantinib combined with lanreotide in gastroenteropancreatic and thoracic neuroendocrine tumors: rationale and protocol of the phase II LOLA trial | BMC Cancer | Full Text
This is a multicenter, open-label, double cohort, non comparative, non-randomized, three-stage phase II trial aiming to assess the safety and activity of the combination of cabozantinib and lanreotide in patients with unresectable, advanced or metastatic WD G2-3 GEP-NETs with Ki-67 ≥ 10% (including pancreatic NET, small intestine NET, stomach NET, colon and rectum NET), thoracic NETs (including typical and atypical carcinoids of the lung and thymus) independently of proliferation index and...
Tumor-Agnostic Precision Medicine from the AACR GENIE Database: Clinical Implications
For decades, cancer management has relied primarily on microscopic examination of tumor tissue with focus on understanding its exact pathology, including the extent of infiltration and the tissue of origin (1). Tumors have been, therefore, managed according to their location in the human body and management guidelines have made this distinction clear by being developed in a site-specific approach.
A phase Ib, open-label study evaluating the safety and efficacy of ipatasertib plus rucaparib in patients with metastatic castration-resistant prostate cancer
Purpose: To report the safety and efficacy of ipatasertib (AKT inhibitor) combined with rucaparib (PARP inhibitor) in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with second-generation androgen-receptor inhibitors.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with de
Contact de, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack